Biotech Venture Funding January 2026

Private financings from January 2026 — Company, date, round, investors, therapeutic area, and a one-line "what they do." Latest VC deals here → 2026 VC Tracker Last updated: 01 Feb 2026

Breakthru Medicine Series A

Date: 29-Jan-2026 | Size: US$60M | Therapeutic area: Oncology (multi-modality platform)

Investors: Not disclosed (press release notes board/investors including Dave Morehead; Fred Eshelman (Eshelman Ventures); Mark Gergen)

What they do: Oncology company developing "disruptive therapeutic modalities" for solid tumors; platform spans small molecules, next-gen ADC payloads, and molecular glues (details of specific programs not publicly disclosed at announcement).

Tenpoint Therapeutics Series B + Credit Facility

Date: 28-Jan-2026 | Size: US$235M total (US$85M Series B + US$150M term loan) | Therapeutic area: Ophthalmology (presbyopia)

Investors: Series B led by Janus Henderson, EQT Nexus, Hillhouse, British Business Bank; existing EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio, Wille; term loan facility from Hercules Capital

What they do: Commercial biotech focused on rejuvenating vision in the aging eye; financing supports commercialization/launch of YUVEZZI (carbachol + brimonidine) for presbyopia (once-daily dual-agent eye drop).

Sensorion Public Financing / Reserved Offering

Date: 28-Jan-2026 | Size: €60M (incl. €20M strategic) | Therapeutic area: Genetic medicine (hearing loss)

Investors: Sanofi (€20M strategic); existing Redmile Group, Artal (advised by Invus), Sofinnova Partners; other investors incl. Cormorant Asset Management, Coastlands Capital, Sphera Healthcare

What they do: Clinical-stage biotech developing genetic medicines to restore/treat/prevent hearing loss; proceeds support SENS-601 (GJB2 gene therapy) advancement toward clinic and continued development of SENS-501.

TRex Bio Financing

Date: 27-Jan-2026 | Size: US$50M (oversubscribed) | Therapeutic area: Immunology / inflammation (tissue Treg biology)

Investors: New Janus Henderson Investors, Balyasny Asset Management, Affinity Asset Advisors; existing Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris Partners, SV Health Investors

What they do: Clinical-stage biotech developing precision immunoregulatory medicines based on tissue Treg biology; proceeds support continued development of TRB-061 (TNFR2 agonist) in atopic dermatitis and advancement of preclinical programs TRB-071/TRB-081 toward the clinic.

CORXEL Series D

Date: 22-Jan-2026|Size: US$287M (up to)|Therapeutic area: Cardiometabolic (obesity / T2D)

Investors: New SR One, TCG Crossover (TCGX), RA Capital, HBM Healthcare Investments, SymBiosis, Adage, Invus, SilverArc (+ others); existing RTW Investments, Hengdian Group Capital

What they do: Clinical-stage cardiometabolic biotech advancing CX11, an oral small-molecule GLP-1 receptor agonist; proceeds support ongoing U.S. Phase 2 obesity study, planned global Phase 2 in T2D, and Phase 3 preparations (plus other cardio-metabolic programs).

Mendra Series A

Date: 22-Jan-2026|Size: US$82M|Therapeutic area: Rare disease (asset acquisition + AI-enabled development)

Investors: Co-led OrbiMed, 8VC, 5AM Ventures; participation Lux Capital, Wing VC

What they do: Builds a portfolio by acquiring underdeveloped rare disease assets and using AI across development + commercialization (e.g., patient identification, trial enrollment, global access) to shorten timelines for underserved patient populations.

ErVimmune Series A

Date: 21-Jan-2026|Size: €17M|Therapeutic area: Oncology (immuno-oncology / therapeutic cancer vaccines)

Investors: Seventure Partners; SPRIM Global Investments (plus access to non-dilutive support from Bpifrance / France 2030)

What they do: Developing off-the-shelf therapeutic cancer vaccines targeting shared HERV-derived tumor antigens; lead candidate ErVac01 is designed for "cold" tumors (e.g., triple-negative breast cancer, ovarian) with funding supporting first-in-human clinical development.

Infinitopes Seed Extension

Date: 21-Jan-2026|Size: US$35M|Therapeutic area: Oncology (cancer vaccines / immuno-oncology)

Investors: Co-led Octopus Ventures, Amplify Bio; new Macmillan Cancer Support; existing Cancer Research Horizons, Manta Ray Ventures

What they do: Clinical-stage precision cancer vaccine company advancing ITOP1 to prevent recurrence in oesophageal cancer, enabled by its antigen discovery platform.

Think Bioscience Series A

Date: 20-Jan-2026|Size: US$55M|Therapeutic area: Rare disease / small-molecule discovery

Investors: Led Regeneron Ventures, Innovation Endeavors, Janus Henderson Investors; participation T.A. Springer, CE-Ventures, MBX Capital, YK Bioventures; returning AV8 Ventures, CU Innovations, Buff Gold Ventures

What they do: Uses synthetic biology to uncover new "footholds" on hard targets for small-molecule drugging; lead program targets mutants driving Noonan syndrome.

Exciva Series B

Date: 20-Jan-2026|Size: €51M|Therapeutic area: Neuropsychiatry

Investors: Co-led EQT Life Sciences (LSP Dementia Fund), Gimv; participation Fountain Healthcare Partners, LifeArc Ventures, Carma Fund, Modi Ventures, Andera Partners, LBBW

What they do: Clinical-stage neuropsychiatry company advancing Deraphan into Phase 2 for agitation associated with Alzheimer's disease.